ImmunityBio (IBRX) Depreciation & Amortization (CF) (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $4.4 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 14.39% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 4.47% decrease from a year earlier, with the FY2025 full-year figure at $15.5 million, down 11.56% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $4.4 million, up from $3.9 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for IBRX reached as high as $5.2 million in Q4 2022 and fell as low as $3.8 million in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $4.4 million across 5 years, with a median of $4.4 million in 2022.
• Across the five-year window, Depreciation & Amortization (CF) soared 45.37% in 2022 and declined 15.94% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $5.2 million in 2022, then fell by 12.67% to $4.6 million in 2023, then fell by 9.33% to $4.1 million in 2024, then slipped by 6.6% to $3.9 million in 2025, then increased by 13.32% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $4.4 million in Q1 2026, $3.9 million in Q4 2025, and $4.0 million in Q3 2025.